The use of Mohs surgery has skyrocketed over the past few years – 248 percent from 1996 to 2008, according to Medicare data. The procedure is heralded as being the “preferred treatment” for certain types of skin cancer and boasts a cure rate of 98 to 99 percent. But Mohs is relatively expensive, costing about $200 more than excision, another standard therapy.
The story focuses on the financial aspects of Mohs and weighs that against the perceived benefits patients receive when choosing this therapy over other alternatives. But the article reads a bit like an advertisement for Mohs – touting its benefits without any mention of potential harms and limitations of the procedure. It also falls short on explaining whether Mohs is truly more expensive than standard excision, and why some groups are concerned about the surgery’s overuse.
Skin cancer is becoming increasingly common with the global aging population and the thinning of the Earth’s ozone. In an era when policymakers talk about curbing spiraling health care costs, the average number of adults being treated for skin cancer is ever increasing, while treatment costs have more than doubled. An insightful piece shedding light on the economics of health care becomes even more important, especially when it can explain why certain, expensive treatments are (or should be) favored over other cheaper, proven therapies.
The main focus of the story is the higher cost of Mohs surgery, which is quoted to be around $1,100 per case, compared to about $900 for conventional excision. While that’s seemingly simple enough to understand, the issue gets confusing when the story quotes a doctor who calls Mohs a “bargain.” He says Mohs is actually less expensive because it involves a single payment to one doctor, whereas excision causes reimbursement to be spread out to the surgeon, pathologist, and lab. The story offers no evaluation of these contradictory claims. The piece also talks about Medicare and Medicaid cutting payments for Mohs and mentions a past proposal of limiting reimbursement to physicians. But it does not explicitly state whether most health insurance policies would cover the procedure for patients.
We’ll award a satisfactory rating since the story is primarily about costs. But we wish it had made clearer distinctions between the cost of performing the procedure, reimbursement, and patient charges.
The reporter makes clear the benefits of Mohs surgery in exchange for its high costs. The article states the procedure spares more tissue and produces better cosmetic results than conventional excision while boasting a cure rate of 98 to 99 percent, according to unidentified studies. The article also does a good job explaining when Mohs would be an appropriate intervention. Mohs is optimal, the article says, when the non-melanomas cover cosmetically important areas.
While we would have liked to have seen some seen some data supporting the statement about the cosmetic benefits of Mohs, we’ll call the overall discussion here good enough for a satisfactory.
The story cautions that Mohs is not a one-stop fix, as it relates a story of a patient who needed additional help from a plastic surgeon for her multi-step reconstruction.
But no discussion of harms is included in the story, nor are the risks of potential complications, such as nerve damage, bleeding and infection. The piece only mentions the benefits of Mohs, with no mention of disadvantages and limitations of the surgery compared to other traditional therapies.
Mohs surgery logs an impressive cure rate of 98 to 99 percent, according to unnamed studies in the article. But these figures could have been more accurately described and attributed in the article.
The following questions come to mind:
(Note: In our original review, the following statement appeared, but has now been left in place with a strikethrough because one of our readers challenged the accuracy of the statement that “Moh’s surgery is actually standard for treatment of melanoma.”)
In addition, the article could have done a better job of explaining that Moh’s surgery is actually standard for treatment of melanoma, a less common but more deadly form of skin cancer compared with the carcinomas described in the story. Until recently, Moh’s surgery has not been customary for these less common nonmelanoma skin cancers.
The story does not engage in disease mongering. It explained the “epidemic” of skin cancer with reliable data from the US Centers for Disease Control and Prevention.
The story quotes a Fox Chase Cancer Center dermatologist and two of his patients regarding their experience with Mohs. We also hear from two other physicians who are experts in the procedure. One talked about how Mohs is “misperceived” as expensive. The other talked about the controversy of the surgery’s categorization in the medical field.
We’ll award a satisfactory here to recognize the breadth of perspectives offered, but with the following caveat: All of the expert sources appear to have some investment in the procedure and may be biased to view it favorably. It would have been interesting to hear from a totally objective source about why Mohs is more expensive than other therapies, or why the surgery seems to be overused by dermatologists.
The article talks about typical therapies for non-melanomas in a doctor’s office, including topical drugs, freezing or lasering.
The story establishes Mohs as the “preferred treatment for the most common types of skin cancer” and adds that its use has skyrocketed to 248 percent from 1996 to 2008. The story also discusses a proposal to limit who can perform the surgery, which theoretically might decrease availability of the procedure.
The article touches upon the procedure’s history, stating that Wisconsin surgeon Frederic E. Mohs developed the process in the 1940s. It makes clear that Mohs is not a novel approach.
We couldn’t find a similar press release online for this story. Furthermore, the article quotes two independent dermatologists from the American College of Mohs Surgery and from the American Academy of Dermatology. We can be sure from this original reporting that the story isn’t based on a press release.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments (2)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
George Maxted
February 6, 2015 at 10:00 amGives short shrift to cryotherapy – destruction of the lesion by freezing. We treat cervical cancer that way, why not skin cancer?
Cecilia Eichenberger
October 7, 2018 at 5:12 pmBut I suspect this article doesn’t consider the plastic surgeon brought in to patch up the hole created by digging out the bad cells. $200 difference from doctor’s method in office is not major, but Medicare surely doesn’t cover the plastic surgeon. That’s what I want to know. Thanks for an answer.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like